The effectiveness of metformin in patients with metabolic syndrome and nonalcoholic fatty liver disease

Cover Page


The mechanism of action of metformin is realized through activation of cAMP-dependent protein kinase, leading to a decrease hepatic glucose production as well as to decrease the synthesis of triglycerides and an increase in fat oxidation. Several studies have demonstrated the positive effect of the drug in non-alcoholic fatty liver disease, manifested in reducing the activity of enzymes, reducing the size of the liver and insulin resistance. The aim of our study was to evaluate the effectiveness of metformin in patients with metabolic syndrome and nonalcoholic fatty liver disease. The study found that the use Siofor 850 mg 2 times a day in conjunction with a reduced-calorie nutrition in patients with metabolic syndrome and nonalcoholic fatty liver disease leads to a significant reduction in insulin resistance associated with decreased activity of transaminases, improvement of metabolic parameters. The therapy Siofor majority of patients (60%) with metabolic syndrome and nonalcoholic fatty liver disease achieved a clinically significant weight loss and improved body composition. Application Siofor improves lifestyle changes in obese patients with non-alcoholic liver disease dirovoy and metabolic disorders.

About the authors

S A Butrova

Endocrinology Research Centre, Moscow

A Yu Eliseeva

Endocrinology Research Centre, Moscow

A V Il'in

Endocrinology Research Centre, Moscow



  1. Богомолов П.О., Шульпекова Ю.О. Неалкогольная жировая болезнь печени: стеатоз и неалкогольный стеатогепатит. // Клинические перспективы в гастроэнтерологии, гепатологии. - 2004. - №3. - С.20-26.
  2. Болезни печени и желчевыводящих путей: Руководство для врачей под ред. В.Т. Ивашкина. / 2-е изд. -М.: «М-Вести» 2005; с- 536.
  3. Реброва О.Ю. Статистический анализ медицинских данных. Применение пакета прикладных программ STATISTICA. - М., 2002.
  4. Adams L.A., Angulo P. Treatment of non-alcoholic fatty liver disease. Postgraduate medical Journal. 2006; 82; 315-322.
  5. Ahmed M. H., Byrne C.D. Non-alcoholic steatohepatitis. // In The Metabolic syn- drome. Ed. by Byrn C.D. and Wild S.H., 2005; 279-303.
  6. Alba L. M., Lindor, K. Review article: non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 2003; 17 (8): 977- 986.
  7. Baily CI, Turner RC. Metformin. N Engl. J. Med. 1996; 334: 574-79.
  8. Carr DB, Utzschneider KM, Hull RL et al. Intra- abdominal fat is a major determi- nant of the National Cholesterol Education Program Adult Treatment Panel III cri- teria for the metabolic syndrome. Diabetes 2004; 53: 2087-94
  9. Cortez-Pinto H., Camilo M.E., Baptista A., De Oliveira A.G., De Moura M.C. Non- alcoholic fatty liver: another feature of the metabolic syndrome? Clin Nutr., 1999; 18(6): 353-358.
  10. Fassio E, Alvarez E, Dominguez N, et al. Natural history of nonalcoholic steato- hepatitis: a longitudinal study of liver biopsies. Hepatology 2004; 40: 820-6.
  11. Houmard JA, Tanner CJ, Slentz CA, et al. Effect of the volume and intensity of exercise training on insulin sensitivity. J Appl Physiol 2004; 96:101-6.
  12. Lam TK, Carpentier A, Lewis GF, van de Werve G, Fantus IG, Giacca A Mechanisms of the fatty acid-induced increase in hepatic glucose production. Am J Physiol Endocrinol Metab 2003; 284: 863-73.
  13. Lin, H. Z., Yang, S. Q., Chuckaree, C, Kuhajda, F., Ronnet, G., Diehl, A. M. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat. Med., 2000; 6 (9): 998-1003.
  14. Marchesini, G., Brizi, M., Morselli-Labate, A. M., Bianchi, G., Bugianesi, E., McCullough, A. J., Forlani, G., Melchionda, N. Association of nonalcoholic fatty liver disease with insulin resistance. Am. J. Med., 1999 ;107 (5): 450-455.
  15. Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Zoli, M., Melchionda, N. Metformin in non-alcoholic steatohepatitis. Lancet, 2001; 358 (9285): 893-894.
  16. Medina J., Ferdandez-Salazar L.I., Garcia-Buey L., Moreno-Otero R. Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis. Diabetes Care. 2004; 27: 2057-2066.
  17. Moghetti P, Castello R, Negry C, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syn- drome: a randomized, double- blind, placebo-controlled 6- month trial, fol-lowed by open, long- term clinical evalution. J. Clin. Endocrinol. Metab. 2000; 85:139-46.
  18. Nair S, Diehl AM, Wiseman M, et al. Metformin in the triement of non- alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther 2004; 20: 23-8.
  19. Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 1990; 99: 1408-13.
  20. Scheen, A. J., Luyckx, F. H. Nonalcoholic steatohepatitis and insulin resistance: interface between gastroenterologists and endocrinologists., Acta Clin. Belg., 2003;58 (2): 81-91.
  21. Sheth, S. G., Gordon, F. D., Chopra, S. Nonalcoholic steatohepatitis., Ann. Intern. Med., 1997; 126(2): 137-145.
  22. Tiikkainen M, Hakkinen AM, Korsheninnikova E et al. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004; 53: 2169-76.
  23. Uygun A, Kadayifci A, Yesilova Z et al. Serum leptin levels in patients with nonal- coholic steatohepatitis. Am J Gastroenterol 2000; 95: 3584-3589.
  24. Uygun A., Kadayifci A., Isik А. Т., Ozgurtas, Т., Deveci S., Tuzun A., Yesilova Z., Gulsen M., Dagalp K. Metformin in the treatment of patients with non-alcoholic steatohepatitis., Aliment. Pharmacol. Ther., 2004;19 (5): 537-544.



Abstract - 938

PDF (Russian) - 603



Copyright (c) 2008 Бутрова С.А., Елисеева А.Ю., Ильин А.В.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies